A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition
See the original post:
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine...
CHICAGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
Read the original:
Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021
RENO, NV, Aug. 17, 2021 (GLOBE NEWSWIRE) -- XcelPlus International Inc. (OTC PINK: XLPID) announced today that it has received a signed letter of intent to build plasma gasifiers for a landfill removal consortium based in India.
Here is the original post:
XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium
New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability
See the original post here:
Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion...
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the second quarter 2021.
See the original post here:
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and...
-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Follow this link:
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
KEEGO HARBOR, Mich., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a letter to shareholders from Chief Executive Officer Andrew Dahl.
Continued here:
Zivo Bioscience, Inc. Issues Letter to Shareholders
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2021 financial results and provide a business update.
Go here to see the original:
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
See the article here:
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
View post:
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units